[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infection-uti\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infection-uti":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100659434","automatic-versus-as-needed-follow-up-after-hospitalization-for-children-with-medical-complexity-100659434",false,"NCT07864636","Automatic Versus As-Needed Follow-up After Hospitalization for Children With Medical Complexity","AFTERCARE: Automatic Versus Family-directed Transition Follow-up After Hospitalization: Evaluating Randomization, Caregiver Acceptability, and Recruitment fEasibility","AFTERCARE","Inclusion Criteria\n\n1. Children aged 1 to younger than 17 years at hospital admission.\n2. Chronic medical conditions affecting at least two body systems.\n3. Hospitalized on a general pediatric, complex care or equivalent service for a respiratory infection, urinary tract infection, skin or soft-tissue infection, or infectious gastroenteritis.\n4. Expected discharge home, with an adult parent or legal guardian available to provide consent and complete study activities.\n\nExclusion Criteria\n\n1. Enrollment after hospital day 30.\n2. Primary care follow-up already scheduled or recommended within seven days after discharge, or a strong family or clinician preference that makes randomization unacceptable.\n3. History of cancer or organ, bone marrow or stem-cell transplantation.\n4. A new type of medical equipment needed at home, or planned home intravenous nutrition or antibiotics.\n5. Selected complicated infections or infection-specific high-risk conditions.\n6. Foster care, hospice care or discharge to an institutional care setting.","ALL","1 Year","16 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection.\n\nFamilies will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.",[28,29,30,31,32],"Children With Medical Complexity","Respiratory Tract Infections (RTI)","Urinary Tract Infection (UTI)","Acute Gastroenteritis","Skin and Soft Tissue Infection",[34,35,36,37],"Pediatric hospitalization","Postdischarge follow-up","Caregiver-directed care","Feasibility trial","NOT_YET_RECRUITING","2026-10-04",{"date":41,"type":42},"2026-10-08","ACTUAL",{"date":44,"type":22},"2026-10",{"date":46,"type":22},"2028-09",{"name":48,"class":49},"Seattle Children's Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":5},"100369840","phase-4-alternative-prophylaxis-in-female-recurrent-urinary-tract-infections-100369840","NCT04095572","Alternative Prophylaxis in Female Recurrent Urinary Tract Infections","Non-antimicrobial Alternative in Prophylaxis of Recurrent Urinary Tract Infections: a Prospective, Randomised-controlled, Double-blinded, Multicentre Study","AlP-FrUiT","Inclusion Criteria:\n\n* Documented history of rUTI, defined as ≥ 3 episodes of (un)complicated UTI documented by urine culture with the isolation of ≥103 cfu\u002Fml of an identified pathogen in the last year with clinical symptoms OR 2 episodes in the last 6 month\n\nExclusion Criteria:\n\n* No informed consent\n* Concomitant UTI (\\\u003C 7 days prior to randomisation)\n* Ongoing antimicrobial prophylaxis (e.g. for rUTI or for any other reason like endocarditis, transplanted patients under immunosuppression)\n* Ongoing prophylactic strategy (e.g. immunoactive prophylaxis)\n* Documented underlying urogenital abnormality (e.g. significant post voiding residual volume (\\>50 ml), urethral stricture, urethral diverticula, urinary stone, reflux, urinary neoplasia), urological device (e.g. catheter, ureteral stent) or symptomatic pelvic floor disorder (e.g. genital prolapse stage ≥ II)\n* Concomitant disease (i.e. renal insufficiency, diabetes mellitus, corticosteroid use)\n* Urogenital urological or gynecological surgery \\\u003C 6 weeks\n* Known allergy to the study medication\n* Use of spermicides or intrauterine device\n* Pregnancy","FEMALE","18 Years","70 Years",{"count":63,"type":22},50,[65],"PHASE4","Urological pathogens are effected by rising antimicrobial resistance rates due to the frequent use of antimicrobials for treatment and prophylaxis. Intravesical instillation with hyaluronic acid (HA) and chondroitin sulphate (CS) obtained positive outcomes in the treatment of overactive bladder, radiation cystitis and interstitial cystitis by replenishment of the glycosaminoglycan layer of the bladder. This study is to investigate whether intravesical instillation with HA-CS in patients with recurrent urinary tract infections (rUTI) is superior to a placebo instillation in terms of reduction of rate of symptomatic urinary tract infections (UTIs) (based on clinical diagnosis) needing treatment with antimicrobials within 12 months after randomisation.",[68,30],"Urinary Tract Infections",[70,71,72,73,74,75],"Hyaluronic acid (HA)","Chondroitin sulphate (CS)","antimicrobial resistance rates","Intravesical instillation","HA-CS instillations","Recurrent Urinary Tract Infection (rUTI)","RECRUITING","2025-02-18",{"date":79,"type":42},"2025-02-19",{"date":81,"type":42},"2020-10-27",{"date":83,"type":22},"2026-06",{"name":85,"class":49},"University Hospital, Basel, Switzerland"]